Insider Selling: Teladoc Health, Inc. (NYSE:TDOC) Insider Sells 1,000 Shares of Stock

Teladoc Health, Inc. (NYSE:TDOC) insider Daniel Trencher sold 1,000 shares of the company’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $13.21, for a total transaction of $13,210.00. Following the completion of the sale, the insider now directly owns 26,192 shares of the company’s stock, valued at $345,996.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Daniel Trencher also recently made the following trade(s):

• On Monday, March 18th, Daniel Trencher sold 1,000 shares of Teladoc Health stock. The shares were sold at an average price of $15.18, for a total transaction of $15,180.00.
• On Monday, March 4th, Daniel Trencher sold 6,780 shares of Teladoc Health stock. The shares were sold at an average price of $14.52, for a total transaction of $98,445.60.
• On Tuesday, February 20th, Daniel Trencher sold 1,000 shares of Teladoc Health stock. The stock was sold at an average price of $20.64, for a total transaction of $20,640.00.

Teladoc Health Trading Up 0.3 %

NYSE:TDOC opened at $13.18 on Friday. The company has a market capitalization of $2.23 billion, a P/E ratio of -9.84 and a beta of 0.94. The company has a current ratio of 3.54, a quick ratio of 3.47 and a debt-to-equity ratio of 0.66. Teladoc Health, Inc. has a 12 month low of $12.93 and a 12 month high of $30.41. The firm has a fifty day simple moving average of $15.74 and a 200-day simple moving average of $17.95.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Tuesday, February 20th. The health services provider reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.05. The company had revenue of $660.50 million during the quarter, compared to analysts’ expectations of $670.79 million. Teladoc Health had a negative return on equity of 9.22% and a negative net margin of 8.47%. The firm’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.23) EPS. On average, equities research analysts anticipate that Teladoc Health, Inc. will post -1.07 earnings per share for the current year.

Institutional Investors Weigh In On Teladoc Health

A number of large investors have recently bought and sold shares of the company. Granite Bay Wealth Management LLC purchased a new position in Teladoc Health during the 3rd quarter worth approximately $3,675,000. Sowell Financial Services LLC increased its stake in shares of Teladoc Health by 40.8% in the fourth quarter. Sowell Financial Services LLC now owns 18,907 shares of the health services provider’s stock worth $407,000 after acquiring an additional 5,475 shares during the period. Lecap Asset Management Ltd. purchased a new position in shares of Teladoc Health during the fourth quarter worth $1,530,000. Deutsche Bank AG lifted its position in Teladoc Health by 12.4% during the third quarter. Deutsche Bank AG now owns 301,147 shares of the health services provider’s stock valued at $5,598,000 after purchasing an additional 33,287 shares during the period. Finally, Sherbrooke Park Advisers LLC acquired a new position in Teladoc Health during the third quarter valued at $680,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TDOC. Truist Financial cut their price target on Teladoc Health from $23.00 to $17.00 and set a “hold” rating on the stock in a report on Wednesday, March 6th. Royal Bank of Canada reduced their target price on shares of Teladoc Health from $30.00 to $25.00 and set an “outperform” rating for the company in a report on Wednesday, February 21st. Barclays lowered their price target on shares of Teladoc Health from $26.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, February 21st. Needham & Company LLC reaffirmed a “hold” rating on shares of Teladoc Health in a research report on Friday, April 5th. Finally, Citigroup decreased their target price on shares of Teladoc Health from $21.00 to $19.00 and set a “neutral” rating for the company in a research report on Wednesday, February 21st. Eight equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $22.23.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.